Utility of Blue Light Cystoscopy for Post-BCG Bladder Cancer Recurrence Detection: Implications for Clinical Trial Recruitment and Study Comparisons.,The Journal of Urology

当前位置： X-MOL 学术 › J. Urol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Utility of Blue Light Cystoscopy for Post-BCG Bladder Cancer Recurrence Detection: Implications for Clinical Trial Recruitment and Study Comparisons.
The Journal of Urology ( IF 5.9 ) Pub Date : 2021-10-25 , DOI: 10.1097/ju.0000000000002308
Meera R Chappidi ₁ , Heiko Yang ₁ , Maxwell V Meng ₁ , Trinity J Bivalacqua ₂ , Siamak Daneshmand ₃ , Jeffrey M Holzbeierlein ₄ , Hristos Z Kaimakliotis ₅ , Badrinath Konety ₆ , Joseph C Liao ₇ , Kamal Pohar ₈ , Gary D Steinberg ₉ , Jennifer M Taylor ₁₀ , Mark D Tyson ₁₁ , Brian Willard ₁₂ , Yair Lotan ₁₃ , Sima P Porten ₁ , Max Kates ₁₄

Affiliation

Department of Urology, University of California, San Francisco, California.
Division of Urology, University of Pennsylvania, Philadelphia, Pennsylvania.
Department of Urology, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, California.
Department of Urology, University of Kansas, Lawrence, Kansas.
Department of Urology, Indiana University School of Medicine, Indianapolis, Indiana.
Department of Urology, University of Minnesota, Minneapolis, Minnesota.
VA Palo Alto Health Care System, Palo Alto, California.
Department of Urology, Ohio State University Wexner Medical Center, Columbus, Ohio.
Department of Urology, New York University, New York City, New York.
Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, Texas.
Department of Urology, Mayo Clinic Hospital, Rochester, Minnesota.
Lexington Medical Center, West Columbia, South Carolina.
Department of Urology, UT Southwestern Medical Center, Dallas, Texas.
The James Buchanan Brady Urological Institute and Department of Urology, The Johns Hopkins University School of Medicine, Baltimore, Maryland.

The utility of blue light cystoscopy (BLC) in patients receiving Bacillus Calmette Guerin (BCG) during post-treatment cystoscopy is not well understood. Our objective was to determine if BLC improves recurrence detection in non-muscle invasive bladder cancer (NMIBC) patients undergoing BCG.

中文翻译：